Product Description
a highly selective GABA A-alpha5 negative allosteric modulator (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33833333/)
Mechanisms of Action: GABA5 NAM
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Down Syndrome|Stroke|Cognitive Dysfunction|Other|Schizophrenia
Phase 1: Healthy Volunteers|Down Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02534207 |
BP29784 | P1 |
Completed |
Healthy Volunteers |
2015-10-01 |
2019-03-20 |
Treatments |
|
NCT02470832 |
WP29402 | P1 |
Completed |
Healthy Volunteers |
2015-07-01 |
2019-03-20 |
Treatments |
|
NCT02342925 |
WP29394 | P1 |
Completed |
Healthy Volunteers |
2015-05-01 |
2019-03-20 |
Treatments |
|
NCT02254759 |
WP29393 | P1 |
Completed |
Healthy Volunteers |
2014-11-01 |
2019-03-20 |
||
NCT02194244 |
WP28978 | P1 |
Completed |
Healthy Volunteers |
2014-08-01 |
2019-03-20 |
Treatments |
|
NCT01667367 |
BP25611 | P1 |
Completed |
Down Syndrome |
2013-10-01 |
2019-03-19 |
Treatments |
|
NCT01436955 |
BP25543 | P1 |
Completed |
Down Syndrome |
2013-09-01 |
2019-03-19 |
Treatments |
|
NCT01684891 |
WP28214 | P1 |
Completed |
Healthy Volunteers |
2012-10-01 |
2019-03-19 |
Treatments |
|
NCT05307679 |
BP42992 | P2 |
Terminated |
Other |
2024-03-04 |
2024-05-17 |
||
2021-003791-13 |
2021-003791-13 | P2 |
Terminated |
Other |
2024-01-12 |
2025-07-09 |
Treatments |
|
NCT02953639 |
BP39207 | P2 |
Completed |
Schizophrenia|Cognitive Dysfunction |
2019-12-12 |
2021-02-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2015-003227-66 |
STROBE | P2 |
Terminated |
Stroke |
2017-12-12 |
2022-03-13 |
Treatments |
|
NCT02928393 |
BP29937 | P2 |
Terminated |
Stroke |
2017-11-03 |
2019-03-21 |
Treatments |
|
NCT02484703 |
WP28760 | P2 |
Terminated |
Down Syndrome |
2016-08-03 |
2019-03-20 |
||
2013-001263-23 |
CLEMATIS | P2 |
Completed |
Down Syndrome |
2016-05-05 |
2022-03-13 |
Treatments |
|
NCT02024789 |
CLEMATIS | P2 |
Completed |
Down Syndrome |
2016-05-04 |
2019-03-20 |
Treatments |